Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism

被引:138
作者
NowakGottl, U
Koch, HG
Aschka, I
Kohlhase, B
Vielhaber, H
Kurlemann, G
OleszcukRaschke, K
Kehl, HG
Jurgens, H
Schneppenheim, R
机构
[1] UNIV HOSP KIEL,DEPT PAEDIAT,KIEL,GERMANY
[2] UNIV HOSP KIEL,DEPT PAEDIAT RADIOL,KIEL,GERMANY
[3] UNIV HOSP MUNSTER,DEPT PAEDIAT,MUNSTER,GERMANY
[4] UNIV HOSP MUNSTER,DEPT PAEDIAT RADIOL,MUNSTER,GERMANY
关键词
APCR; Gln; 506; Arg; children; venous thrombosis; neonatal stroke;
D O I
10.1046/j.1365-2141.1996.424957.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Resistance to activated protein C (APCR), in the majority of cases due to the point mutation Arg 506 Gin of the factor V gene, has emerged as the most important hereditary cause of venous thromboembolism. Using an activated thromboplastin time (aPTT) based method in the presence of APC together with a DNA technique based on the polymerase chain reaction, we investigated 37 children with venous (V: n=19) or arterial (A: n=18) thromboembolism and matched healthy controls for the presence mutation, In the control group 10 children were detected to be heterozygous for the factor V Leiden mutation, indicating a prevalence of 5.1%. 10/19 children (52%) with venous thrombosis and 7/18 (38%) patients with arterial thromboembolism showed the common factor V gene mutation. Additional inherited coagulation disorders were found in 1/10 (V: 10%) and 2/7 (A: 28%) APC-resistant patients, Inherited coagulation disorders without APCR were diagnosed in 3/9 (V: 33%) and 2/11 (A: 18%) children, Furthermore, we diagnosed exogenous risk factors in 6/10 (V: 60%) and 2/7 (A: 28%) children with thrombosis and APCR. These data are evidence that APCR combined with exogenous reasons may play an important role in the early manifestation of thromboembolism during infancy and childhood.
引用
收藏
页码:992 / 998
页数:7
相关论文
共 15 条
  • [1] IMPAIRMENT OF THE PROTEIN-C ANTICOAGULANT PATHWAY IN A PATIENT WITH SYSTEMIC LUPUS-ERYTHEMATOSUS, ANTICARDIOLIPIN ANTIBODIES AND THROMBOSIS
    AMER, L
    KISIEL, W
    SEARLES, RP
    WILLIAMS, RC
    [J]. THROMBOSIS RESEARCH, 1990, 57 (02) : 247 - 258
  • [2] ANDREW M, 1995, THROMB HAEMOSTASIS, V74, P415
  • [3] ARNOUT J, 1995, THROMB DIATH HAEMO, V73, P1275
  • [4] BANDELLO F, 1994, THROMB HAEMOSTASIS, V72, P39
  • [5] MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C
    BERTINA, RM
    KOELEMAN, BPC
    KOSTER, T
    ROSENDAAL, FR
    DIRVEN, RJ
    DERONDE, H
    VANDERVELDEN, PA
    REITSMA, PH
    [J]. NATURE, 1994, 369 (6475) : 64 - 67
  • [6] THE ANTIPHOSPHOLIPID AND THROMBOSIS SYNDROMES
    BICK, RL
    BAKER, WF
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 1994, 78 (03) : 667 - 684
  • [7] FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C
    DAHLBACK, B
    CARLSSON, M
    SVENSSON, PJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) : 1004 - 1008
  • [8] DAHLBACK B, 1995, THROMB HAEMOSTASIS, V74, P139
  • [9] DAHLBACK B, 1991, THROMB HAEMOSTASIS, V65, P658
  • [10] FAIONI EM, 1994, THROMB HAEMOSTASIS, V72, P643